OKUR - NASDAQ

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.47

+8.5%

HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$61.12M

EPS-4.4000

P/E Ratio-1.02

Earnings Date08/11/2026

62.12M

Assets

-46%

3Y+288.0%

5Y+12.0%

10Y+12.0%

5.93M

Total Liabilities

-46%

3Y-92.0%

5Y-94.0%

10Y-94.0%

56.18M

Total Equity

-46%

3Y-203.0%

5Y-233.0%

10Y-233.0%

OnKure Therapeutics, Inc. Funding & Solvency Profile

OKUR · NASDAQ

Current Assets

Cash & Cash Equivalents59.05M

Net Receivables0.00

Inventory0.00

Other Current Assets1.79M

Total Current Assets61 M

Non-Current Assets

Property, Plant & Equipment1.00M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets273.00K

Total Non-Current Assets1 M

Total Assets

62.12M

Financial Health Analysis

Current Ratio

10.28x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.11x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

55 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

98% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

OnKure Therapeutics, Inc. Balance Sheet

OKUR • NASDAQ

OnKure Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	59.1M	110.8M	29.9M	11.5M	124.7M	53.6M
Short-Term Investments	0.0	0.0	0.0	0.0	23M	0.0
Cash & Short-Term Investments	59.1M	110.8M	29.9M	11.5M	147.7M	53.6M
Prepaids	0.0	2.2M	3.9M	1.2M	0.0	0.0
Other Current Assets	1.8M	0.0	0.0	840K	6.1M	1.4M
Total Current Assets	60.8M	113M	33.8M	13.6M	153.7M	55M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	1M	1.8M	1.9M	2M	212K	69K
Other Non-Current Assets	273K	109K	58K	329K	78K	127K
Total Non-Current Assets	1.3M	1.9M	2M	2.4M	290K	196K
Total Assets	62.1M	114.9M	35.7M	16M	154M	55.2M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.4M	3M	3.4M	2.5M	0.0	0.0
Accounts Payable	1.4M	3M	3.4M	2.5M	0.0	0.0
Accrued Expenses	0.0	3.9M	2M	1.4M	0.0	0.0
Short Term Debt	549K	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	536K	208K	151K	0.0	0.0
Other Current Liabilities	3.9M	3.2M	1.7M	1.5M	6.2M	4.6M
Total Current Liabilities	5.9M	10.5M	7.3M	5.5M	6.2M	4.6M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	92.7M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	167K	36K
Other Non-Current Liabilities	12K	0.0	129.8M	64.4M	444K	0.0
Total Non-Current Liabilities	12K	549K	130.3M	64.9M	611K	92.8M
Capital Lease Obligations	0.0	1.1M	674K	637K	0.0	0.0
Total Liabilities	5.9M	11.1M	137.6M	70.4M	6.8M	97.3M
SHAREHOLDERS' EQUITY
Common Stock	1K	1K	0.0	1K	3K	1K
Additional Paid-In Capital	270.4M	258.6M	209K	2.7M	231.9M	2.8M
Retained Earnings	-214.2M	-154.7M	-102.1M	-57.1M	-84.7M	-45M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	34K	0.0
Total Stockholders' Equity	56.2M	103.8M	-101.8M	-54.4M	147.2M	-42.1M
Total Equity	56.2M	103.8M	-101.8M	-54.4M	147.2M	-42.1M
SUMMARY
Total Liabilities & Equity	62.1M	114.9M	35.7M	16M	154M	55.2M
Total Investments	0.0	0.0	0.0	0.0	23M	0.0
Total Debt	549K	1.1M	674K	637K	0.0	92.7M
Net Debt	-58.5M	-109.7M	-29.2M	-10.9M	-124.7M	39.1M
Shares Outstanding	13,548,200	13,548,200	13,548,200	13,548,200	13,548,200	13,548,200

SEC Filings

OKUR - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 05, 2026	May 05, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 05, 2026	March 31, 2026	2026	View Filing
S-3 S-3 N/A	April 24, 2026	April 24, 2026		View Filing
DEF 14A DEF 14A 2026 N/A	April 21, 2026	June 03, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 30, 2026	March 27, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 12, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 12, 2026	March 12, 2026	2026	View Filing
S-3 S-3 N/A	November 06, 2025	November 06, 2025		View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 06, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 89 filings

Related Guides

Blog Categories

Continue your OKUR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.